The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Publication summary. The terms of TechCrunch AI do not allow reproduction of the full article: read the complete text on the original website.
Source summary (English)
Read the full article
techcrunch.com